AbbVie says hepatitis C regimen gets nod for FDA priority review

June 13, 2014 9:06 PM

8 0

(Reuters) - U.S. regulators have granted priority review for AbbVie Inc's experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus, the company said on Friday.

The priority review means the Food and Drug Administration will likely decide within six months whether to approve the regimen, which was submitted to the agency on April 21.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page